No 35 (2014)

ИСТОРИЯ МОНИКИ

DMITRIY DMITRIEVICH PLETNEV (ON THE OCCASION OF THE 240TH ANNIVERSARY OF YEKATERININSKAYA HOSPITAL, AT PRESENT – M.F. VLADIMIRSKIY MOSCOW REGIONAL RESEARCH AND CLINICAL INSTITUTE (MONIKI))

Paleev N.R., Paleev F.N.

Abstract

.
Almanac of Clinical Medicine. 2014;(35):6-11
pages 6-11 views

CARDIOLOGY

IMMUNOLOGICAL FEATURES OF INFLAMMATORY MYOCARDIAL DISEASES DUE TO VIRAL INFECTIONS

Paleev F.N., Sanina N.P., Makarkov A.I., Mylov N.M., Ostrovskiy E.I., Khishova N.N., Moskalets O.V., Paleev N.R.

Abstract

Background: Autoantibodies to myocardial antigenic epitopes and corresponding autoreactive T cell clones play an important role in myocardial damage and in pathogenesis of infectious immune myocarditis. T lymphocytes subpopulations/regulatory T cells balance as well as T cell-derived cytokines are crucial in the mechanisms of immune regulation in myocarditis. Aim: To assess quantitative parameters and functional characteristics of basic peripheral blood lymphocytes subpopulations in patients with infectious immune myocarditis and post-myocarditis cardiosclerosis. Material and methods: 35 patients with infectious immune myocarditis and 39 patients with post-myocarditis cardiosclerosis were included. Among infectious immune myocarditis patients, 17 patients had advanced congestive heart failure (CHF) (NYHA III), and 18 patients had mild, moderate or no heart failure (NYHA 0-II). Among cardiosclerosis patients, 18 patients had no CHF, and 21 had only mild symptoms of heart failure (NYHA I). 10 healthy volunteers were enrolled in the control group. Populations and subpopulations of peripheral blood lymphocytes and markers of lymphocytes activation were studied using quadricolor laser flow cytometry (FACSCalibur) and suitable monoclonal antibodies (Becton Dickinson, USA). Results: Inflammatory myocardial diseases are characterized by alterations of innate and adaptive immunity. In our study, patients with infectious immune myocarditis and post-myocarditis cardiosclerosis had significantly reduced numbers of natural killer T cells irrespective of CHF symptoms and disease duration. T cell immunity disturbances were characterized by decreased numbers of CD3+CD4+ cells depending from the disease duration and symptoms severity. Patients with infectious immune myocarditis also had increased numbers of B cells. Immune activation was demonstrated both in infectious immune myocarditis and (less prominent) in post-myocarditis cardiosclerosis. Increased expression of early activation marker CD25 was found during the first 2 weeks from the disease onset in patients with infectious immune myocarditis. In 1 month and during the second month of the disease, increased numbers of T cells and non-T lymphocytes were demonstrated along with late activation manifested by the expression of HLA-DR antigen. Different severity of CHF symptoms was associated with different patterns of activation markers. Increased expression of apoptosis marker CD95 was found in both infectious immune myocarditis and post-myocarditis cardiosclerosis; maximal CD95 values were demonstrated in myocarditis patients in 1 month after the disease onset. Conclusion: Disturbances of anti-infection immunity and self-limitation mechanisms of immune reactions play an important role in the development and progression of inflammatory myocardial diseases.

Almanac of Clinical Medicine. 2014;(35):12-21
pages 12-21 views

LECTURE

MENTAL DISORDERS IN ELDERLY PATIENTS WITH INTERNAL DISEASES

Podrezova L.A., Markina T.R., Seyku Y.V.

Abstract

The lecture article describes common mental disorders in elderly patients with somatic and mental diseases combinations. Practice recommendations for internists are presented.
Almanac of Clinical Medicine. 2014;(35):89-93
pages 89-93 views

CYTOKINE PROFILE OF Th1-, Th2- AND Th17-LYMPHOCYTE SUBPOPULATIONS IN INFECTIOUS MYOCARDITIS

Sanina N.P., Paleev F.N., Makarkov A.I., Mylov N.M., Ostrovskiy E.I., Khishova N.N., Moskalets O.V., Paleev N.R.

Abstract

Background: Type 17 T-helpers (Th17) were first identified more than 10 years ago. Though, there are only limited studies on the role of Th17- mediated mechanisms in the immune pathogenesis of acute myocarditis and dilative cardiomyopathy. Aim: To assess specific cytokine profile in patients with infectious immune myocarditis and post-myocarditis cardiosclerosis. Materials and methods: 35 patients with infectious immune myocarditis, 39 patients with post-myocarditis cardiosclerosis and 10 healthy volunteers (control group) were enrolled. 17 subjects with infectious immune myocarditis had manifest heart failure. Mean concentrations of Th1-, Th2- and Th17-derived cytokines were measured using solid-phase enzyme-linked immunosorbent assay panel manufactured by VectorBest ZAO (Russia). For statistical analysis, PASW Statistics software was used. Results: Compared to healthy controls, patients with infectious immune myocarditis had higher serum interferon-gamma (IF-γ) concentrations and more than 3-fold increase of serum interleukin (IL)-4. They also had almost 7-fold increase of IL-17A and Th17 effector cytokines – IL-8 and granulocyte-macrophage colony-stimulating factor (GM-CSF). Patients with infectious immune myocarditis and moderate or no symptoms of heart failure had significantly lower concentrations of IF-γ compared to patients with advanced heart failure. Cytokine concentrations peaked during the first 2 week of the disease, with following decrease. On the contrary, serum IL-4 grew significantly by the end of the first month and during the second month of the disease. Raised concentrations of IL-17A, IL-8 and GM-CSF were found throughout the period from the second week to the second month of the disease. Th17-derived cytokines concentrations were significantly increased in patients with post-myocarditis cardiosclerosis. Compared to the controls, IL-17A almost doubled, IL-8 increased by 51%, and GM-CSF – by 50%. Elevated concentrations of IL-4, IL-17A, IL-8 and GM-CSF were found in patients with duration of post-myocarditis cardiosclerosis less than 6 months. Conclusion: Disorders of anti-infective immunity and deficient self-limitation mechanisms of immune response play an important role in the development and progression of inflammatory myocardial diseases.

Almanac of Clinical Medicine. 2014;(35):22-29
pages 22-29 views

RAYNAUD’S PHENOMENON: A MULTIDISCIPLINARY PROBLEM

Alekperov R.T.

Abstract

Raynaud’s phenomenon (RP) is a common medical condition with prevalence in the population about 3–5%. RP is subdivided into primary form manifesting mainly in children and adolescents, and secondary RP affecting elder patients. Secondary RP is frequently associated with systemic rheumatic disorders, endocrine and hematological diseases and certain infections. It also may be due to exogenous factors. Thus, RP is an actual problem in the practice of rheumatologists, pediatric physicians, infectious diseases specialists, hematologists and other medical practitioners. This clinical lecture discusses in detail current approaches to diagnosis and differential diagnosis of RP.
Almanac of Clinical Medicine. 2014;(35):94-100
pages 94-100 views

SEVERAL POINTS ABOUT INFECTIVE ENDOCARDITIS IN PRESENT-DAY PRACTICE

Gurevich M.A.

Abstract

The article analyzes some special aspects of infective endocarditis in present-day practice. The author describes in detail clinical manifestations of infective endocarditis in the elderly, in patients with previously intact cardiac valves, in persons with myocardial diseases, and in injection drug users.
Almanac of Clinical Medicine. 2014;(35):30-33
pages 30-33 views

CARDIAC GLYCOSIDES IN UP-TO-DATE CLINICAL PRACTICE

Gurevich M.A., Gavrilin A.A.

Abstract

The article reviews the use of cardiac glycosides in patients with chronic heart failure, paroxysmal tachyarrhythmia and chronic atrial fibrillation (rate control). According to the recent studies results cardiac glycosides may be substituted by angiotensin-converting enzyme inhibitors, angiotensin receptor antagonists, diuretics, calcium antagonists and beta-adrenoceptor blockers in order to decrease the risk of cardiac glycoside toxicity and, in some cases, to improve quality of life and prognosis of the patients.
Almanac of Clinical Medicine. 2014;(35):101-105
pages 101-105 views

EMERGENCY STATES IN ARTERIAL HYPERTENSION

Gurevich M.A., Kuz’menko N.A.

Abstract

The article describes in detail potential emergency states in patients with different stages of arterial hypertension with special attention to diagnosis and rational management of hypertensive crisis. Differentiated approach to management of different forms of hypertensive crisis is specified.
Almanac of Clinical Medicine. 2014;(35):34-37
pages 34-37 views

ANTIBACTERIAL THERAPY OF INFECTIVE ENDOCARDITIS

Gurevich M.A., Kuz’menko N.A.

Abstract

The article analyzes the influence of infective endocarditis etiology on the clinical course of the disease. The role of Staphylococci as common pathogens is emphasized. Streptococci have faded in importance, though, streptococcal endocarditis is still a frequent form of the disease. The authors give the data on bactericidal agents active against the main causative microorganisms in endocarditis; doses, rational combinations and adverse effects are specified. Treatment-requiring common cardiac and extra-cardiac complications of infective endocarditis are also characterized.
Almanac of Clinical Medicine. 2014;(35):106-108
pages 106-108 views

CLINICAL EVIDENCE OF THE EFFECTIVENESS OF VIFERON® MEDICATIONS IN THE TREATMENT OF ARVI AND INFLUENZA IN ADULTS

Malinovskaya V.V., Chebotareva T.A., Parfenov V.V.

Abstract

The paper presents a comparative analysis of the results of clinical laboratory trials carried out on the basis of 10 different medical and preventive treatment facilities drawing on the principles and methodology of evidence-based medicine, which confirmed the certainty of clinical effectiveness of Viferon® medications in the treatment of acute respiratory viral infections (ARVI) and influenza in adults. The algorithm included an assessment of antiviral, immunomodulatory, anti-inflammatory, anti-oxidant actions of the medication under the conditions of concurrent, unmasked, randomized, placebo-controlled, clinical immunological studies and a retrospective analysis in keeping with the “Guidelines for Good Clinical Practice”. Thereby, it was shown that the use of Viferon® medications (suppositories, gel) in the treatment of adults with influenza and ARVI, whether with viral or viral-bacterial etiology, contributes to a statistically significant reduction in duration of principal clinical symptoms and the disease as a whole, as well as a decrease of immune and interferon system imbalance and a faster elimination of viral antigens. On the basis of the proven antiviral therapeutic effectiveness and immunomodulatory action, safety and high tolerability, easy-to-administer form in the  outpatient settings, Viferon® has been recommended as a disease-modifying agent in the treatment of influenza and ARVI in adults.
Almanac of Clinical Medicine. 2014;(35):109-115
pages 109-115 views

PULMONOLOGY

RELIABILITY OF BRONCHOALVEOLAR LAVAGE FLUID LYMPHOCYTES COUNT AND BLOOD NEOPTERIN LEVELS AS INFLAMMATORY MARKERS IN SARCOIDOSIS

Terpigorev S.A., Paleev F.N.

Abstract

Background: Sarcoidosis is an inflammatory granulomatous disease of unknown origin. Lungs and thoracic lymph nodes are most frequently affected. To assess inflammatory process activity, disease activity criteria are to be identified. In clinical practice, bronchoalveolar lavage (BAL) fluid lymphocytes count and blood neopterin levels are commonly used for the monitoring of inflammatory activity in sarcoidosis, though, reliability of the methods may be inadequate. Aim: To assess reliability of BAL fluid lymphocytes count and blood neopterin levels as inflammatory markers in pulmonary sarcoidosis. Materials and methods: BAL fluid lymphocytes counts and blood neopterin levels were measured in 111 patients with pulmonary sarcoidosis. 39 patients had stage I sarcoidosis on chest radiographs, 57 patients had stage II, 15 patients had stage III sarcoidosis. In 28 patients, BAL fluid was sampled from different segments of the lung to compare lymphocytes counts. The results were paralleled with pulmonary function tests, radiographic stage and lung parenchyma changes in computed tomography. Results: Lymphocytes counts in BAL fluid correlated with blood neopterin levels (r=0.26, p=0.027), forced vital capacity value (r=-0.24, p=0.04), and did not correlate with sarcoidosis radiographic stage. In 43% of patients, relative lymphocyte counts in BAL fluid samples from different parts of the lung varied significantly (from 5 to 23%). Normal neopterin levels were detected in 40% of patients with active inflammation. Conclusion: Non-uniform pattern of pulmonary inflammation results in variable lymphocytes counts in BAL fluid samples from different parts of the lung. BAL fluid lymphocytes counts and blood neopterin levels should not be used for reliable monitoring of inflammation in sarcoidosis.

Almanac of Clinical Medicine. 2014;(35):38-41
pages 38-41 views

PROGNOSTIC ALGORITHM FOR DISEASE FLOW IN PULMONARY AND THORACIC LYMPH NODES SARCOIDOSIS

Terpigorev S.A., Ilchenko V.A.

Abstract

Background: Sarcoidosis is a systemic granulomatosis commonly affecting respiratory system. Variable and often unpredictable flow of the disease provides rationale for the development of prognostic algorithm. Aim: To detect predictive parameters in pulmonary and thoracic lymph nodes sarcoidosis; to develop prognostic algorithm. Materials and methods: The results of examination of 113 patients (85 women and 28 men, 19–77 years old) with morphologically verified sarcoidosis has been assessed. Clinical manifestations, functional, radiographic (including CT numerical scores) and morphological features of the disease were analyzed against 3-year outcomes in prednisolon/hydroxychloroquine-treated or treatment-naive patients. Results: Radiographic stage, CT-pattern scores, several parameters of pulmonary function tests (DLCO, RV, FEV1, FVC) and dyspnoe had the greatest prognostic significance for disease flow. Prognostic accuracy was 87.8% and increased to 94.5% after one-year dynamics of symptoms was taken into account. Therapy with systemic glucocorticosteroids did not influence outcomes in sarcoidosis with asymptomatic enlargement of thoracic lymph nodes. Conclusion: We have developed an algorithm for prognosis assessment in pulmonary sarcoidosis. Taking into account the results of patients follow-up significantly improves the accuracy of the prognosis.
Almanac of Clinical Medicine. 2014;(35):42-48
pages 42-48 views

CYTOTOXIC LYMPHOCYTES: THE ROLE IN INFLAMMATION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE EXACERBATION AND REMISSION

Raspopina N.A., Shuganov E.G., Paleev F.N., Salmasi Z.M., Shuganov A.E.

Abstract

Background: Despite the number of publications related to the expression of surface antigens of periphery blood lymphocytes in chronic obstructive pulmonary disease (COPD), algorithm for interpreting of the results and implicating pathogene-tic treatments still needs to be developed. Aim: To assess the role of cytotoxic lymphocytes in the maintaining of inflammation in COPD. Materials and methods: To examine immune status in 37 patients with COPD exacerbation or remission and 24 healthy donors (control group), blood cytotoxic T-lymphocytes and NK-cells contents were measured using indirect immunofluorescence method. Absolute and relative numbers of lymphocytes expressing CD3, CD4, CD8, CD16, CD20, CD23, CD25, CD54, CD71, CD72, HLA-DR, CD95 antigens, membrane immunoglobulins  M (mIgM) and G (mIgG) were estimated. Results: In COPD, significantly increased numbers of blood cytotoxic lymphocytes were demonstrated independently from the disease stage (p < 0.001). During COPD exacerbation, significant elevations of CD4, CD8, CD20, CD72, NК-cells numbers, serum mIgM and mIgG were demonstrated. During remission, CD20 and CD72 content returned to normal, though, increased numbers of other cytotoxic cells persisted promoting inflammation and progressive damage of pulmonary and bronchial tissues. Conclusion: Observed changes may be due to excessive stimulation of T-cell component of immune system in COPD patients both in exacerbation and remission. Relative reduction of total T-lymphocyte numbers indicates non-specific (non-infectious) inflammation type. High cytotoxic potential of immune system results in pulmonary damage and promotes development of pneumosclerosis and emphysema.


Almanac of Clinical Medicine. 2014;(35):49-53
pages 49-53 views

CLINICAL AND IMMUNOLOGICAL CORRELATIONS IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND BRONCHIAL ASTHMA

Shuganov E.G., Raspopina N.A., Salmasi Z.M.

Abstract

Background: To improve differential diagnosis of chronic obstructive pulmonary disease (COPD) and bronchial asthma (BA), identification of new biological markers is needed. Aim: To differentiate between COPD and BA using modern immunological methods. Materials and methods: Surface markers of peripheral blood lymphocytes were studied in patients with COPD (n=37) and BA (n=49) exacerbation. Immunological status was also assessed in 24 healthy controls. Results: In both COPD and BA, typical inflammatory changes of T-lymphocytes, B-lymphocytes and NK-cells counts were found. Lymphocyte surface phenotype changes were significantly different in COPD and BA. In COPD, a significant elevation of blood cytotoxic T-lymphocytes (CD8+) up to 34% was demonstrated; on the contrary, in BA patients, cytotoxic T-lymphocytes (CD8+) decreased to 21%. CD16+ lymphocytes (NK-cells) were significantly increased (up to 33%) in COPD patients and corresponded to normal values in BA (~10%). Conclusion: Differences in biological markers in COPD and BA reflect distinct pathogenesis of the diseases and may be used for differential diagnosis.
Almanac of Clinical Medicine. 2014;(35):54-59
pages 54-59 views

EFFECTS OF PHOTOHEMOTHERAPY ON THE CLINICAL COURSE OF BRONCHIAL ASTHMA

Ostrovskiy E.I., Karandashov V.I., Shatokhina S.N., Sanina N.P., Ryzhkova O.Y., Katlomina E.M., Paleev N.R.

Abstract

Background: Anti-inflammatory and immunoregulatory effects of photohemotherapy have been demonstrated in myocarditis, chronic obstructive pulmonary disease, some autoimmune and other disorders. There are only limited reports on the use of photohemotherapy in bronchial asthma (BA). Aim: To assess the influence of blue- and red-light photohemotherapy on clinical course of BA. Materials and methods: 480 hospitalized patients with persistent moderate BA and mild (44.5%) or moderate (55.5%) exacerbation were randomized to receive standard therapy of asthma exacerbation and photohemotherapy (treatment group, n=250) or standard therapy only (control group, n=230). Blue-light photohemotherapy (photodiode apparatus Solaris, n=220) or redlight photohemotherapy (helium-neon gas laser, n=30) was applied according to the schedule: procedure duration – 30 minutes, number of sessions – 5–7, every 2–3 days. Results: In asthma exacerbation, adding photohemotherapy to standard treatment was associated with more rapid improvement of clinical symptoms: maximal total asthma scores were achieved by the day 7–10 in patients with mild exacerbation and by the day 10–14 in patients with moderate exacerbation. Therapeutic effects of blue-light photohemotherapy were superior to those of red-light photohemotherapy. The data of 3-year follow-up supported the role of photohemotherapy in achieving asthma control: in the treatment group, proportion of patients with total control of asthma was 1.3-fold higher and one-year hospitalization number was lower by 34.8% compared with the controls. Conclusion: Blue-light and red-light photohemotherapy positively influences the clinical course of asthma and is associated with faster remission achievement and reduction of duration and frequency of hospitalizations.
Almanac of Clinical Medicine. 2014;(35):60-65
pages 60-65 views

CLINICAL AND IMMUNOLOGICAL EFFECTS OF CARBOCYSTEINE IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Shuganov E.G., Salmasi Z.M., Shuganov A.E.

Abstract

Background: Chronic obstructive pulmonary disease (COPD) is one of the commonest diseases characterized by persistent distal airways inflammation. Thus, anti-inflammatory therapy should be the basis of COPD treatment. There is only limited evidence supporting the efficacy of mucolytics like carbocysteine in the preventing COPD exacerbations in inhaled corticosteroid-naïve patients. Aim: To study clinical and immunological effects of carbocysteine in COPD. Materials and methods: During first 2 months, 30 patients with stage II COPD (mean age 55.9±1.2  years old) were treated with inhaled glucocorticosteroids and beta2-adrenoceptor agonists ‘as required’. Thereafter, the standard therapy was continued in 15 patients; in other 15 patients carbocysteine 1500 mg/day was added. Immune status was studied bi-monthly in all patients: to detect lymphocytes with expression of CD3, CD4, CD8, CD72-antigens and CD23, CD71, CD95 and HLA-DR activation markers, monoclonal antibodies were used. Quality of life was assessed using adapted Russian version of St. George’s Respiratory Questionnaire (SGRQ). Results: Compared with the anti-inflammatory therapy, adding carbocysteine to standard therapy of COPD was associated with significantly better quality of life after 4 months of therapy (less negative changes of symptoms and activity scores and improvement of psycho-social function: changes of relevant SGRQ scores were -3.4 and -8.0; -1.9 and -3.8; 0.4 and -0.76, respectively). After 4 months, carbocysteine-treated patients demonstrated better improvements in shortness of breath, cough and sputum scores compared with the control group (2 and 2.2; 1.5 and 1.9; 0.8 and 1.2, respectively). In carbocysteine group, clinical symptoms improvement correlated with positive changes of immunological status. The patients demonstrated greater significant elevation of total T-lymphocytes (especially CD8+-cells), decreased B-cells and increased expression of CD95-antigen compared with the standard therapy group. Conclusion: Carbocysteine may be recommended as an obligate part of therapy in COPD patients.
Almanac of Clinical Medicine. 2014;(35):66-70
pages 66-70 views

RHEUMATOLOGY

CARDIAC ARRHYTHMIA AND CONDUCTION DISTURBANCES IN PATIENTS WITH SYSTEMIC SCLEROSIS

Alekperov R.T., Cheremukhina E.O., Novikova D.S., Anan’eva L.P.

Abstract

Aim: To assess prevalence of certain cardiac arrhythmias and conduction disturbances in the Russian population of systemic sclerosis patients using standard 12-lead and 24-hour electrocardiography (ECG); to estimate correlation between cardiac arrhythmia and clinical features of systemic sclerosis. Materials and methods: 80 systemic sclerosis patients and 60 sex- and age-matched controls were included. All patients underwent standard 12-lead and 24-hour ECG. Results: Arrhythmias on standard 12-lead ECG were demonstrated in 14 patients (17.5%) including sinus arrhythmia in 2 cases and premature beats in 13 cases (16%). Supraventricular (SV) and ventricular (V) ectopic beats were recorded in 5 (6%) and 7 (9%) patients, respectively; in one patient both SV and V ectopic beats were found. ECG signs of focal fibrosis were demonstrated in 9 patients (11%). In 24-hour ECG, frequencies of SV and V ectopic beats were 40 and 65%, respectively. Compared to the controls, systemic sclerosis patients had significantly higher prevalence and severity of cardiac arrhythmia. 36% of patients had high grade ventricular premature beats, associated with potential risk of life-threatening arrhythmia and sudden cardiac death. Conclusion: Cardiac arrhythmias and conduction disturbances are found in the majority of patients with systemic sclerosis. Standard ECG does not reflect true prevalence of cardiac arrhythmia in systemic sclerosis. In systemic sclerosis patients, 24-hour ECG is recommended as obligate method for initial examination and treatment efficacy control.
Almanac of Clinical Medicine. 2014;(35):71-76
pages 71-76 views

EXACERBATION OF ANKYLOSING SPONDYLITIS AFTER LOW-DOSE METHOTREXATE THERAPY

Orlov-Morozov A.V.

Abstract

Background: Efficacy of methotrexate in ankylosing spondylitis (AS) is disputable. Nevertheless, methotrexate is still used for disease-modifying therapy of AS. Aim: To assess efficacy and safety of methotrexate in AS patients. Materials and methods: It was an open comparative study of efficacy of methotrexate (n=12) versus standard therapy (n=12) in AS patients. Results: Negative results of methotrexate therapy were obtained. In the majority of patients methotrexate therapy was associated with increased joint pain, swelling and morning stiffness as well as elevation of erythrocyte sedimentation rate, fever and visceritis. Worsening of symptoms was regarded as exacerbation of inflammatory process. The study was terminated prematurely. Conclusion: Methotrexate demonstrated no therapeutic effect in AS patients. In AS, methotrexate should be administrated under close physician control in order to ensure treatment safety
Almanac of Clinical Medicine. 2014;(35):77-83
pages 77-83 views

PSYCHOSOMATICS

PSYCHOSOMATICS IN THE CONTEXT OF THE DEVELOPMENT OF INTEGRATIVE MEDICINE

Krasnov V.N., Paleev N.R.

Abstract

Integrative medicine represents a promising modern approach to examination and treatment of large population of patients managed by the specialists in psychosomatics and somatopsychiatry. In Russia, experience of teamwork is scarce and non-common. However, implementation of this model of work is encouraged by accumulating evidence of existence of common mechanisms of the development of numerous somatic diseases and psychiatric disorders.
Almanac of Clinical Medicine. 2014;(35):84-88
pages 84-88 views

CLINICAL CASES

MASKS OF HYPOTHYROIDISM (A CLINICAL CASE)

Ilchenko V.A., Lebedeva A.O., Gordienko B.V., Bolotin E.V.

Abstract

This is a case presentation of hypothyroidism with symptomatic hypothyroid myopathy and 10-fold creatine kinase increase.

 

Almanac of Clinical Medicine. 2014;(35):116-118
pages 116-118 views

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies